biotech8 hours ago
Roche Halts Emugrobart Obesity Trial After Failed Interim Analysis
Roche has terminated development of emugrobart, a myostatin-blocking antibody intended to preserve muscle during weight loss, after an interim analysis of its phase 2 Gyminda trial indicated the drug was unlikely to meet its endpoints. The company has returned the asset to its Japanese subsidiary, Chugai, which plans to resume development for spinal muscular atrophy and seek licensing partners. This setback follows earlier failures in muscular dystrophy trials and occurs as Roche expands its obesity portfolio through other deals.